Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 292, Issue 6, 2007, Pages

  Peter, Jean Christophe ^a   Nicholson, Janet R ^a   Heydet, Déborah ^a   Lecourt, Anne Catherine ^a   Hoebeke, Johan ^b   Hofbauer, Karl G ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b CNRS   (France)

Author keywords

Agouti related protein; Body weight; Food intake; G protein coupled receptor; Immunization

Indexed keywords

CYCLIC AMP; FAT; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES; BODY WEIGHT; CELL LINE; EATING; FEMALE; HUMANS; HYPOTHALAMUS; KIDNEY; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELANOCORTIN, TYPE 4;

EID: 34447558562     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00878.2006     Document Type: Article

References (28)

1. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23: 2223-2226, 2002.
2. Bohen SP, Troyanskaya OG, Alter O, Warnke R, Botstein D, Brown PO, Levy R. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 100: 1926-1930, 2003.
3. Bronner G, Sattler AM, Hinney A, Soufi M, Geller F, Schafer H, Maisch B, Hebebrand J, Schaefer JR. The 103I variant of the melanocortin 4 receptor is associated with low serum triglyceride levels. J Clin Endocrinol Metab 91: 535-538, 2006.
4. Chen M, Celik A, Georgeson KE, Harmon CM, Yang Y. Molecular basis of melanocortin-4 receptor for AGRP inverse agonism. Regul Pept 136: 40-49, 2006.
5. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 8: 571-578, 2005.
6. Cowley MA. Hypothalamic melanocortin neurons integrate signals of energy state. Eur J Pharmacol 480: 3-11, 2003.
7. Elies R, Fu LX, Eftekhari P, Wallukat G, Schulze W, Granier C, Hjalmarson A, Hoebeke J. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. Eur J Biochem 251: 659-666, 1998.
8. Ellacott KL, Cone RD. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res 59: 395-408, 2004.
9. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 141: 3072-3079, 2000.
10. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, DelValle J, Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 268: 15174-15179, 1993.
11. Kamel R, Eftekhari P, Garcia S, Berthouze M, Berque-Bestel I, Peter JC, Lezoualc'h F, Hoebeke J. A high-affinity monoclonal antibody with functional activity against the 5-hydroxytryptaminergic (5-HT(4)) receptor. Biochem Pharmacol 70: 1009-1018, 2005.
12. Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 4: 328-329, 1998.
13. Lebesgue D, Wallukat G, Mijares A, Granier C, Argibay J, Hoebeke J. An agonist-like monoclonal antibody against the human beta2-adrenoceptor. Eur J Pharmacol 348: 123-133, 1998.
14. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42: 2759-2767, 2003.
15. Mobini R, Fu M, Wallukat G, Magnusson Y, Hjalmarson A, Hoebeke J. A monoclonal antibody directed against an autoimmune epitope on the human beta1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma 19: 135-142, 2000.
16. Neimark J, Briand JP. Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. Pept Res 6: 219-228, 1993.
17. Nordheim U, Nicholson JR, Dokladny K, Dunant P, Hofbauer KG. Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats. Peptides 27: 438-443, 2006.
18. Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L. Central melanocortin receptors regulate insulin action. J Clin Invest 108: 1079-1085, 2001.
19. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278: 135-138, 1997.
20. Peter JC, Tugler J, Eftekhari P, Maurice D, Hoebeke J, Roegel JC. Effects on heart rate of an anti-M2 acetylcholine receptor immune response in mice. FASEB J 19: 943-949, 2005.
21. Peter JC, Wallukat G, Tugler J, Maurice D, Roegel JC, Briand JP, Hoebeke J. Modulation of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2 receptor antibody fragments. J Biol Chem 279: 55697-55706, 2004.
22. Schuna AA, Megeff C. New drugs for the treatment of rheumatoid arthritis. Am J Health Syst Pharm 57: 225-234, 2000.
23. Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, Johnston DB, Bakshi R, Palucki B, Weinberg DH, MacNeil T, Kalyani RN, Tang R, Stearns RA, Miller RR, Tamvakopoulos C, Strack AM, McGowan E, Cashen DE, Drisko JE, Hom GJ, Howard AD, MacIntyre DE, van der Ploeg LH, Patchett AA, Nargund RP. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1- (4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl] -2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 45: 4589-4593, 2002.
24. Small CJ, Kim MS, Stanley SA, Mitchell JR, Murphy K, Morgan DG, Ghatei MA, Bloom SR. Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes 50: 248-254, 2001.
25. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR, Vaisse C. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 114: 1158-1164, 2004.
26. Tarnow P, Schoneberg T, Krude H, Gruters A, Biebermann H. Mutationally induced disulfide bond formation within the third extracellular loop causes melanocortin 4 receptor inactivation in patients with obesity. J Biol Chem 278: 48666-48673, 2003.
27. Tota MR, Smith TS, Mao C, MacNeil T, Mosley RT, Van der Ploeg LH, Fong TM. Molecular interaction of Agouti protein and Agoutirelated protein with human melanocortin receptors. Biochemistry 38: 897-904, 1999.
28. Yang YK, Dickinson CJ, Zeng Q, Li JY, Thompson DA, Gantz I. Contribution of melanocortin receptor exoloops to Agouti-related protein binding. J Biol Chem 274: 14100-14106, 1999.